Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment.
about
N-terminal fragment of B-type natriuretic peptide (NT-proBNP), a marker of cardiac safety during antipsychotic treatmentHeart failure in patients with chronic kidney disease: a systematic integrative reviewCoagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparinN-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF).Serum 25-hydroxyvitamin D is not related to cardiac natriuretic peptide in nulliparous and lactating women.Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations.Towards a blood test for heart failure: the potential use of circulating natriuretic peptides.Ozone-Oxidative Preconditioning Prevents Doxorubicin-induced Cardiotoxicity in Sprague-Dawley RatsBiomarkers in predicting mortality and treatment in hemodialysis patientsRelationship between CCR and NT-proBNP in Chinese HF patients, and their correlations with severity of HF.Triiodothyronine and brain natriuretic peptide: similar long-term prognostic values for chronic heart failure.The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure.Association of cardiac and renal function with extreme N-terminal fragment pro-B-type natriuretic peptide levels in elderly patients.Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives.The effects of super-flux (high performance) dialyzer on plasma glycosylated pro-B-type natriuretic peptide (proBNP) and glycosylated N-Terminal proBNP in end-stage renal disease patients on dialysis.Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP.Vitamin D deficiency contributes to the reduction and impaired function of naïve CD45RA⁺ regulatory T cell in chronic heart failureNT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function.N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure.Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease.N-Terminal Pro-B-type Natriuretic Peptide Is Useful to Predict Cardiac Complications Following Lung Resection Surgery.Essential biochemistry and physiology of (NT-pro)BNP.Brain and other natriuretic peptides: molecular aspects.NT-proBNP in heart failure: therapy decisions and monitoring.Comparison of endothelial vasodilator function, inflammatory markers, and N-terminal pro-brain natriuretic peptide in patients with or without chronotropic incompetence to exercise test.ProBNP-derived peptides in cardiac disease.Variability of NT-proBNP plasma and urine levels in patients with stable heart failure: a 2-year follow-up study.Brain natriuretic peptide in the contemporary management of congestive heart failure.N-terminal proBNP: a novel biomarker for the diagnosis, risk stratification and management of congestive heart failure.Clinical value of plasma B-type natriuretic peptide assay in pediatric pneumonia accompanied by heart failureClinical use and pathogenetic basis of laboratory tests for the evaluation of primary arterial hypertension.Dyslipidemia in patients with systemic lupus erythematosus: Association with disease activity and B-type natriuretic peptide levels.Predicting the outcome of hip fracture patients by using N-terminal fragment of pro-B-type natriuretic peptide.Biomarkers of cardiovascular damage.Nonheart failure-associated elevation of amino terminal pro-brain natriuretic peptide in the setting of sepsis.Breed differences in natriuretic peptides in healthy dogs.Early detection and significance of structural cardiovascular abnormalities in patients with Type 2 diabetes mellitus.Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.Analysis of the severity and prognosis assessment of aged patients with community-acquired pneumonia: a retrospective study.The Relationship between Serum NT- Pro-BNP Levels and Prognosis in Patients with Systolic Heart Failure.
P2860
Q24804676-43545E91-C5E4-494A-BB6C-49520EBA41D1Q26824149-358F7E91-5746-4762-86D7-8D12635D3E59Q28208874-EB96FF4C-6A53-49CD-B217-291DCED9CB9DQ30908647-2754B94D-0F04-4DED-A3FD-D4F3F6DBBCDBQ33403893-46564AE4-F435-4F88-B7F2-BEB245E4D819Q33875592-7AA29C55-597C-4376-B366-11B7998B411BQ33962030-3FCA7E7D-6099-410C-9DA2-A2C04DDC74AFQ33982934-EC1CB98C-55E9-4A73-B4D6-7CBE26DB447FQ34062442-EC350A15-F077-4AA1-830F-2CBC5C3E8AB9Q34183461-8DE2F21B-4B25-46B1-98DF-8698DF3A0CD6Q34190826-9605C776-3122-4610-9981-64B2C10BC053Q34346282-DB9CAB7A-5450-4A6E-9C07-8878CFB2F9CAQ34352658-81CEDEAC-1EE4-44C6-96F4-A5D5485739A4Q34448373-139FE7F7-3423-4CCE-B050-A8895F7F2BF1Q35131225-50E01941-54C4-4F15-A7B0-812C6D074B6DQ35375245-02B076EA-B25F-4195-AD75-EE72130B70FEQ35578732-75565D94-2174-4CEF-80FE-FCA5B1463D3DQ35580797-0E03EDE3-BEDB-405E-93EB-22E8C9CBB1B1Q35581367-B0E7D64C-9720-4881-85AF-C753BF8ABF4EQ35596013-AEA14795-0CE7-43C9-B8B7-B05A3AD503BBQ35644493-A74D0330-629B-4AD4-8F9D-F66ACE9BC030Q35677297-D1E74B9C-15E8-4E49-BD95-25ED9391A8F7Q35677302-54916DB0-025B-43ED-BFD3-B99F630E346DQ35677310-2F008537-0915-40D8-85B0-9B783BD28A98Q35771801-EB0B7DA9-402F-4FA4-90FE-81AE435D4596Q35847164-82A79E82-8DD3-4ED4-8EAD-5E502229F590Q36014073-F3BB9A6D-49A3-4D12-8056-C87DAA383A9FQ36050481-43604BAB-C4EC-478D-B2C6-EAA3CB8D9724Q36124913-95C079FA-CA81-491A-AA5B-1B8BEF2DF374Q36334557-F7F14BCA-26F6-420E-84B8-477086CDCD24Q36359500-DE97B3A5-BB57-4015-B821-399868733F34Q36502274-15E0847E-E386-43C4-8D04-AE25C53A0F70Q36625349-6DA8ABCE-9B79-4062-92D6-AA936D93E490Q36836546-9F7A281F-AA56-41FF-9285-B0EAB986D67AQ36861287-2C7B3E15-9C6E-425C-8821-B8D8008E6BB8Q36873330-50B9D73B-18E2-4E3C-9F8B-DEF5738740FEQ37038967-72E667FD-F164-40D8-8336-5FFA4FF7EA88Q37108057-A82BF62A-88A4-4C10-9EAD-BBAD023CF926Q37274618-4C067337-748D-42FD-97AA-1CC22AC140FEQ37301554-174FD923-24DF-4672-B236-7064A3B557CE
P2860
Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Immunoreactive amino-terminal ...... marker of cardiac impairment.
@en
Immunoreactive amino-terminal pro-brain natriuretic peptide
@nl
type
label
Immunoreactive amino-terminal ...... marker of cardiac impairment.
@en
Immunoreactive amino-terminal pro-brain natriuretic peptide
@nl
prefLabel
Immunoreactive amino-terminal ...... marker of cardiac impairment.
@en
Immunoreactive amino-terminal pro-brain natriuretic peptide
@nl
P2093
P1476
Immunoreactive amino-terminal ...... w marker of cardiac impairment
@en
P2093
A M Richards
E A Espiner
M G Nicholls
R N Doughty
P304
P356
10.1046/J.1365-2265.1997.2361058.X
P50
P577
1997-09-01T00:00:00Z